Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$0.79
-0.03 (-3.66%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-12.7M · quality 53.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$41M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-83.9%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2006–2025 · 19 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-40585.7%
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $28000.0 · net income $-14.3M · FCF $-11.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||||||
| Revenue | $28000.00 | $28000.00 | — | $651000.00 | — | — | — | — | $2.2M | $8.0M | $17.4M | $19.3M | $5.2M | $29.5M | $2.4M | $1.1M | — | — | — | — | — |
| Net Income | $-14.3M | $-14.3M | $-13.0M | $-18.4M | $47.8M | $-35.1M | $-40.4M | $-53.2M | $-47.1M | $-51.5M | $-43.2M | $-24.4M | $-33.4M | $-23.4M | $-33.4M | $-20.1M | $-14.3M | $-20.1M | $-20.7M | $-9.6M | $-3.8M |
| EBITDA | $-14.4M | $-14.4M | $-12.6M | $-9.8M | $61.9M | $-34.0M | $-39.1M | $-52.5M | $-35.2M | $-36.9M | $-29.9M | $-18.0M | $-36.8M | $-6.1M | — | — | — | — | — | — | — |
| EPS | -0.34 | -0.34 | -0.50 | -1.29 | 5.72 | -5.86 | — | — | — | -22.00 | -19.00 | -12.00 | -18.20 | -11.80 | -30.20 | — | — | — | — | — | — |
| Operating Margin | -48157.1% | -48157.1% | — | -2594.3% | — | — | — | — | -1660.9% | -483.8% | -184.1% | -103.6% | -721.7% | -22.6% | — | — | — | — | — | — | — |
| Net Margin | -51035.7% | -51035.7% | — | -2826.0% | — | — | — | — | -2192.0% | -644.3% | -248.6% | -126.7% | -639.3% | -79.4% | -1393.6% | -1875.1% | — | — | — | — | — |
| Balance Sheet | |||||||||||||||||||||
| Debt/Equity | — | — | — | — | 0.25 | -0.14 | -0.24 | -0.50 | 0.79 | -0.31 | -3.49 | 0.49 | 0.39 | 0.20 | 0.25 | 0.87 | — | — | — | — | — |
| Current Ratio | 5.30 | 5.30 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||||||
| Free Cash Flow | $-11.4M | $-11.4M | $-12.7M | $-17.6M | $-28.7M | $-31.8M | $-40.4M | $-54.6M | $-29.9M | $-32.2M | $-33.1M | $-21.4M | — | $-3.8M | $-25.4M | $-17.3M | $-12.2M | $-19.5M | — | — | — |
| Returns | |||||||||||||||||||||
| ROE | -83.9% | -83.9% | -162.5% | -130.4% | 218.9% | 97.8% | 72.4% | 128.5% | -1108.6% | 141.1% | 808.6% | -73.7% | -71.5% | -32.0% | -98.6% | -115.1% | 21.8% | 38.0% | 62.0% | 73.0% | 101.4% |
| Valuation | |||||||||||||||||||||
| P/E | — | — | — | — | 0.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | — | — | — | — | 0.10 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 1.97 | 1.97 | 2.00 | 0.79 | 0.74 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||||||
| Revenue Growth | — | — | — | — | — | — | — | — | -73.1% | -53.9% | -9.9% | 269.2% | -82.3% | 1132.3% | 123.3% | — | — | — | — | — | — |
| EPS Growth | 32.0% | 32.0% | 61.2% | -122.6% | — | — | — | — | — | -15.8% | -58.3% | 34.1% | -54.2% | 60.9% | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+61.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.50 → -0.34
Residual
+61.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.